Mangata Networks Selected by 5G Open Innovation Lab to Help Drive Early Adoption and Innovation of 5G Technology
16.9.2020 19:00:00 EEST | Business Wire | Press release
Mangata Networks announced today that it has been selected as a member of the 5G Open Innovation Lab, a global ecosystem of developers, start-ups, enterprises, academia and government institutions, focused on helping start-ups utilize 5G to develop new capabilities, use cases and market categories. Mangata Networks will work closely with the Lab’s founding partners including Intel, T-Mobile and other partners to further develop its 5G over satellite network solution. MangataEdgeTM will be a bit more than a satellite terminal integrating microEdge cloud computing with 5G radio access networking capability.
Brian Holz, CEO of Mangata Networks said “the 5G Open Innovation Lab is a fantastic opportunity for our team. We look forward to working with TMobile, Intel and their partners to further develop and define our core terrestrial networking product, ensuring seamless integration into 5G networks at affordable costs. MangataEdgeTM will allow operators to bring the cloud directly to businesses, communities and individuals, enabling them to effectively do their bit.”
Unique to the Lab’s approach is its focus on unifying an independent ecosystem by bringing together technology, financial and community partners and forward-thinking customers from industries such as media and entertainment, transportation, oil and gas, manufacturing, and retail.
Integrating satellite over 5G in a seamless, cost-effective manner enables information exchange and service delivery by communities and individuals not well connected today. The 5G Open Innovation Lab will give Mangata Networks access to leading edge technology, partnerships, resources, and environment to ensure their 5G product is a success.
“The 5G OI Lab is an extraordinary opportunity for developers to work directly with technology and business leaders to design and bring to life their vision and dreams for new 5G applications,” said Jim Brisimitzis, managing partner of the 5G OI Lab. “This is not just any startup program. We are building a true partner ecosystem that will bring knowledge, resources and capital together to change the world in profound ways.”
About the 5G Open Innovation Lab
The 5G Open Innovation Lab (5G OI Lab) is a global ecosystem of developers, start-ups, enterprises, academia and government institutions working together to fuel the development of new 5G capabilities and market categories that will transform the way we work, live and play both now and in the future. The Lab provides developers at all stages unparalleled access to open platforms, enterprises and markets needed to create, test and deploy new use cases and innovations for 5G. To learn more about the Lab and its portfolio of companies, please visit https://www.5GOILab.com/ or follow us on Twitter at @5GOILab.
About Mangata Networks
Mangata Networks, a joint venture with Intellectual Ventures Invention Science Fund, is a satellite enabled telecommunications company seeking to transform human potential into action. Our solution: creating a seamless global network to support businesses, communities, and individuals to do their bit. Our single core network allows rapid scaling of data connectivity across geographies. With a global footprint, our technology can be mobilized by businesses to reach their highest potential anywhere at an affordable price. To learn more about Mangata Networks, please visit https://www.mangatanetworks.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005591/en/
Contact information
Calysto Communications
Laura Borgstede
Lborgstede@calysto.com
404-266-2060 x. 11
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom